Today, the American Cancer Society and the American Cancer Society Cancer Action Network submitted a comment letter to the Office of Management and Budget strongly opposing a proposed rule that would change the federal government’s grantmaking framework.
Nearly 200 patient advocacy, public health and health care professional organizations sent a letter to the Senate declaring their strong support for the Clinical Trial Modernization Act (S. 4440/H.R. 3521). The bipartisan, bicameral legislation would help remove cost and geographic barriers that keep patients from enrolling and participating in clinical trials. The bill was introduced in the U.S. Senate by Sens. Tim Scott (R-SC) and Mark Warner (D-VA) in April 2026 and in the U.S. House of Representatives in May 2025 by Reps. Raul Ruiz (D-CA) and August Pfluger (R-TX).
A new bill that would improve access to clinical trials was recently introduced in the U.S. Senate. Sponsored by Senators Tim Scott (R-S.C.) and Mark Warner (D-Va.), the Clinical Trial Modernization Act (S. 4440) would help reduce cost and geographic barriers, making it easier for patients to take part in clinical trials. U.S. Representatives Raul Ruiz (D-Calif.) and August Pfluger (R-Texas) introduced the House version (H.R. 3521) of this legislation in May 2025.
Today, the American Cancer Society Cancer Action Network (ACS CAN) was joined by 24 other organizations in proposing the Health and Human Services Office of Inspector General adopt a new regulatory safe harbor from the Anti-kickback Statute that would allow clinical trial sponsors to financially support patients to offset indirect or non-medical costs associated with clinical trial participation, such as travel, parking and lodging.
New federal legislation that would make it easier for all cancer patients to participate in clinical trials was introduced today in the House of Representatives. Sponsored by U.S. Reps. Raul Ruiz (D-Calif.) and August Pfluger (R-Texas), the Clinical Trial Modernization Act would help remove cost and geographic hurdles that prevent patients from participating in clinical trials.
The American Cancer Society Cancer Action Network (ACS CAN) today released a report examining the most common patient barriers to cancer clinical trial enrollment. Made public at ACS CAN’s annual national policy forum, the report found only about one in four (27%) patients has access to clinical trials where they are being treated. Yet, if asked to enroll in an available trial, more than half of eligible patients typically agree to do so.